IR-MED has secured a $500,000 grant from the Israel Innovation Authority (IIA) to advance the development of DiaSafe, an AI-powered device which uses noninvasive spectrographic technology to provide real-time optical readings of biomarkers for early detection of diabetic foot ulcers
The device targets a condition that affects up to 183m people worldwide. Diabetic foot ulcers are a major cause of preventable death for people with diabetes, with and 19% to 34% of people globally with diabetes these, or up to 183 million people, will develop a diabetic foot ulcer during their lifetime. Of these, 20%, or up to 37m people, will require lower-extremity amputation, and 10%, or 18m people, will die within one year of their first diabetic foot ulcer diagnosis. Accordingly, early intervention can reduce death rates associated with diabetic foot complications
The company plans to initiate its first in-human clinical trial as part of the development process.
To find out more, CLICK HERE.
